PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$3.21
+0.10 (+3.05%)
Open$3.21
Previous Close$3.12
Day High$3.40
Day Low$3.09
52W High$6.94
52W Low$1.11
Volume—
Avg Volume2.02M
Market Cap562.42M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Buy
19 analysts
Price Target
+1,245.5% upside
Current
$3.21
$3.21
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.45M | 5.54M | 80.41M |
| Net Income | -236,899,730 | -327,047,779 | -21,315,556 |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% |
| EBITDA | -236,601,876 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | — | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |